NeuroSearch, Glaxo start Phase II studies of NS2359 depression
Forbes - COPENHAGEN (AFX) - NeuroSearch AS said it and GlaxoSmithKline PLC (GSK) have started Phase II clinical development of drug candidate NS2359 (GSK372475) in patients diagnosed with major depressive disorder. Under a development and licensing agreement
Source: www.forbes.com
Antidepressants Reduce Suicide in Children Despite FDA Warning
HealthCentral.com - Researchers are concerned children may not get the depression treatment they need. Dr. Gibbons said, "There's concern there is a lot of untreated depression in children and the potential for increases in the rates of suicide." The black-box warning
Source: www.healthcentral.com
Treating Workers' Depression Helps Companies' Bottom Line
Forbes - Our study calculates what employers' return on their investment would be if they purchased enhanced depression treatment programs for their workers," he said. The study was funded by the U.S. National Institute of Mental Health. More information The
Source: www.forbes.com
Families for Depression Awareness Launches Adult Depression Wellness
PR Newswire - It can take multiple tries to find the most helpful antidepressant, according to STAR*D, the nation's largest depression treatment study sponsored by the National Institute of Mental Health. Depression is also the leading cause of suicide. Monitoring
Source: sev.prnewswire.com
FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression
PR Newswire - WILMINGTON, Del., Oct. 20 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL(R) (quetiapine fumarate) for the treatment of patients with depressive episodes
Source: sev.prnewswire.com
Click here for more information about beck depression inventory beck depression inventory
<< Home